Abstract
Schizophrenia affects approximately 1% of the world population, and the majority of pharmacologically based treatments for this disorder are ligands that interact with monoaminergic transmission. However, there is a wealth of evidence that various neuropeptides are often co-released with monoamine neurotransmitters, and that ligands acting at neuropeptide receptors modulate monoaminergic transmission as well as schizophrenia-related behaviors in preclinical animal models. Such neuropeptide systems include neurotensin, cholecystokinin, corticotropin releasing factor, neuropeptide Y, oxytocin, opioid peptides, tachykinins, thyrotropin-releasing hormone, and orexins. The purpose of this review will be to summarize the existing preclinical and clinical literature on the role of various neuropeptide systems as modulators of schizophrenia-related behaviors, and the potential of targeting these systems for the development of novel antipsychotic medications.
Keywords: Schizophrenia, antipsychotic, dopamine, neuropeptide, positive symptoms, negative symptoms, cognitive deficits.
CNS & Neurological Disorders - Drug Targets
Title:Neuropeptide Systems and Schizophrenia
Volume: 12 Issue: 5
Author(s): Amber L. LaCrosse and M. Foster Olive
Affiliation:
Keywords: Schizophrenia, antipsychotic, dopamine, neuropeptide, positive symptoms, negative symptoms, cognitive deficits.
Abstract: Schizophrenia affects approximately 1% of the world population, and the majority of pharmacologically based treatments for this disorder are ligands that interact with monoaminergic transmission. However, there is a wealth of evidence that various neuropeptides are often co-released with monoamine neurotransmitters, and that ligands acting at neuropeptide receptors modulate monoaminergic transmission as well as schizophrenia-related behaviors in preclinical animal models. Such neuropeptide systems include neurotensin, cholecystokinin, corticotropin releasing factor, neuropeptide Y, oxytocin, opioid peptides, tachykinins, thyrotropin-releasing hormone, and orexins. The purpose of this review will be to summarize the existing preclinical and clinical literature on the role of various neuropeptide systems as modulators of schizophrenia-related behaviors, and the potential of targeting these systems for the development of novel antipsychotic medications.
Export Options
About this article
Cite this article as:
LaCrosse L. Amber and Olive Foster M., Neuropeptide Systems and Schizophrenia, CNS & Neurological Disorders - Drug Targets 2013; 12 (5) . https://dx.doi.org/10.2174/1871527311312050010
DOI https://dx.doi.org/10.2174/1871527311312050010 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease
Current Pharmaceutical Design Ag/CdS Nanocomposite: An Efficient Recyclable Catalyst for the Synthesis of Novel 8-Aryl-8H-[1,3]dioxolo[4,5-g]chromene-6-carboxylic Acids under Mild Reaction Conditions
Combinatorial Chemistry & High Throughput Screening Chronic Kidney Disease and Thrombosis
Current Pediatric Reviews Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Development and Characterization of Cassia grandis and Bixa orellana Nanoformulations
Current Topics in Medicinal Chemistry Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Bioavailability Through PepT1: The Role of Computer Modelling in Intelligent Drug Design
Current Computer-Aided Drug Design Mexiletine Metabolites: A Review
Current Medicinal Chemistry Recent Advances in the Synthesis of 1,3-Azoles
Current Topics in Medicinal Chemistry Use of Dopaminergic Agents in the Treatment-Resistant Depression
Current Psychopharmacology A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia
Current Drug Safety Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research Opioids and Mechanical Ventilation
Current Drug Targets Neurohypophyseal Dysfunction During Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review on Phytochemistry and Pharmacology of Medicinal as well as Poisonous Mushrooms
Mini-Reviews in Medicinal Chemistry Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets CGRP-Receptor Antagonism in Migraine Treatment
CNS & Neurological Disorders - Drug Targets Technological Options for the Production of Health-Promoting Proteins and Peptides Derived from Milk and Colostrum
Current Pharmaceutical Design